Ascend Wellness (OTCMKTS:AAWH – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Ascend Wellness to similar businesses based on the strength of its analyst recommendations, dividends, risk, institutional ownership, earnings, profitability and valuation.
Valuation & Earnings
This table compares Ascend Wellness and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Ascend Wellness | $500.58 million | -$118.19 million | -0.59 |
| Ascend Wellness Competitors | $17.36 billion | $3.18 billion | 555.16 |
Ascend Wellness’ competitors have higher revenue and earnings than Ascend Wellness. Ascend Wellness is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ascend Wellness | 0 | 1 | 0 | 0 | 2.00 |
| Ascend Wellness Competitors | 7850 | 13806 | 25845 | 1039 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 27.65%. Given Ascend Wellness’ competitors stronger consensus rating and higher possible upside, analysts clearly believe Ascend Wellness has less favorable growth aspects than its competitors.
Volatility and Risk
Ascend Wellness has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Ascend Wellness’ competitors have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.
Profitability
This table compares Ascend Wellness and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ascend Wellness | -23.49% | N/A | -11.15% |
| Ascend Wellness Competitors | -2,391.71% | -206.09% | -14.88% |
Insider and Institutional Ownership
17.3% of Ascend Wellness shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 21.9% of Ascend Wellness shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Ascend Wellness competitors beat Ascend Wellness on 8 of the 13 factors compared.
Ascend Wellness Company Profile
Ascend Wellness Holdings is a U.S. cannabis company that cultivates, processes, and sells cannabis products in regulated state markets. Its business combines cultivation and manufacturing facilities with a network of retail dispensaries. The company offers products including cannabis flower, edibles, concentrates, and vape products. Its portfolio includes brands such as Ozone and Simply Herb, alongside products from other suppliers sold through its retail stores. Founded in 2018, Ascend has developed operations across markets including Illinois, Michigan, Ohio, Massachusetts, New Jersey, and Pennsylvania.
Receive News & Ratings for Ascend Wellness Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascend Wellness and related companies with MarketBeat.com's FREE daily email newsletter.
